Advertisement

Advertisement

2022 San Antonio Breast Cancer Symposium

Breast Cancer

Expert Point of View: Nancy Chan, MD

Nancy Chan, MD, Director of Breast Cancer Clinical Research at NYU Langone’s Perlmutter Cancer Center, New York, commented on the monarchE analysis for The ASCO Post. She noted that the study investig...

Breast Cancer

Update From monarchE: Benefit of Abemaciclib Increases Over Time in Early-Stage Breast Cancer

Results of a planned interim overall survival analysis of the phase III monarchE trial offered further support for the addition of abemaciclib to adjuvant endocrine therapy for patients with hormone r...

Breast Cancer

Palbociclib/Fulvestrant Does Not Improve Progression-Free Survival After Progression on a CDK4/6 Inhibitor in Metastatic Breast Cancer

The combination of palbociclib and fulvestrant did not prolong progression-free survival compared to fulvestrant alone in patients with hormone receptor–positive/HER2-negative metastatic breast cancer...

Breast Cancer

Can Younger Women With Hormone Receptor–Positive Breast Cancer Safely Pause Endocrine Therapy to Pursue Pregnancy?

Preserving fertility is a driving concern for many young women with breast cancer. Many of these women have hormone receptor–positive breast cancer and are treated with adjuvant endocrine therapy for ...

Breast Cancer

SERENA-2 Trial: Camizestrant Improves Progression-Free Survival in Advanced Breast Cancer

The oral selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, as compared with fulvestrant, in previously treated postmenopausal women with advanced breast canc...

Breast Cancer

Neoadjuvant T-DXd Demonstrates Activity in Phase II Study of Patients With HER2-Low Breast Cancer

A pilot study provides a signal that the novel HER2 antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd), is active in the neoadjuvant setting in patients with HER2-low breast cancer. Overa...

Breast Cancer

Capivasertib Plus Fulvestrant Doubles Progression-Free Survival in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

The combination of capivasertib, an AKT pathway inhibitor, plus fulvestrant, an estrogen receptor antagonist, significantly improved progression-free survival compared with fulvestrant alone in patien...

Breast Cancer

Can Women With Two or Three Ipsilateral Breast Cancer Sites Safely Undergo Breast-Conserving Therapy?

Many women with two or three cancerous lesions in the breast can safely undergo lumpectomy followed by radiation therapy, according to the results of a prospective phase II trial reported at the 2022 ...

Breast Cancer

EMERALD Trial: Elacestrant vs Standard Endocrine Monotherapy for Advanced Breast Cancer After CDK4/6 Inhibition

Elacestrant—an investigational oral selective estrogen receptor degrader (SERD)—achieved longer progression-free survival vs standard-of-care endocrine monotherapy as second- or third-line therapy in ...

Breast Cancer
Immunotherapy

Expert Point of View: Neelima Vidula, MD

Commenting on the DESTINY-Breast03 presentation at the 2022 San Antonio Breast Cancer Symposium, Neelima Vidula, MD, a medical oncologist at Mass General Cancer Center, said: “The results highlight th...

Breast Cancer
Immunotherapy

T-DXd Confirmed as Preferred Second-Line Therapy for Metastatic HER2-Positive Breast Cancer

The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) proved to be superior to the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1), significantly improving progression-free sur...

Breast Cancer

Expert Point of View: Aditya Bardia, MD, MPH

Aditya Bardia, MD, MPH, Director of Breast Cancer Research and Associate Professor at Harvard Medical School, and attending physician at Mass General Cancer Center, Boston, commented on the RIGHT Choi...

Breast Cancer

Ribociclib Plus Endocrine Therapy vs Combination Chemotherapy for Patients With Breast Cancer: Focus on Those in Visceral Crisis

According to findings from the phase II RIGHT Choice trial, many premenopausal patients with metastatic hormone receptor–positive, HER2-negative breast cancer experiencing visceral crisis are best tre...

breast cancer

Sean Khozin, MD, MPH, on Randomized Trials vs Real-World Evidence in Patients With Advanced Cancer

Sean Khozin, MD, MPH, of the Massachusetts Institute of Technology, discusses the “external validity deficits” of randomized clinical trials, which still involve only about 5% of adults with cancer, w...

Breast Cancer
Survivorship

TAILORx Update: 12-Year Recurrence and Survival Outcomes for Patients With Early-Stage Breast Cancer

Long-term recurrence and survival data are now available from the groundbreaking TAILORx trial. With 12 years of follow-up, the updated analysis—reported by Sparano et al at the San Antonio Breast Can...

breast cancer

Prudence A. Francis, MD, on Premenopausal ER-Positive Breast Cancer: Past, Present, and Future

Prudence A. Francis, MD, of the Peter MacCallum Cancer Centre, discusses an update of the SOFT trial, which showed that adding ovarian function suppression (OFS) to adjuvant tamoxifen for premenopausa...

Breast Cancer
Immunotherapy

Efficacy of Sacituzumab Govitecan in TROPiCS-02 Trial Not Dependent on Trop-2 Expression

The latest analysis of the TROPiCS-02 breast cancer trial shows that sacituzumab govitecan-hziy is effective in patients with a wide range of Trop-2 expression levels. The findings were reported at th...

Breast Cancer

MonarchE Update: Benefit of Abemaciclib Increases Over Time

Results of a planned interim overall survival analysis of the phase III monarchE trial offer further support for the addition of abemaciclib to adjuvant endocrine therapy for patients with hormone rec...

breast cancer

Andrea De Censi, MD, on Noninvasive Breast Cancer: 10-Year Results on Low-Dose Tamoxifen

Andrea De Censi, MD, PhD, of Italy’s E.O. Ospedali Galliera, discusses phase III findings showing that low-dose tamoxifen (so-called babytam) given for 3 years still significantly prevents recurrences...

breast cancer

Ann H. Partridge, MD, MPH, on Interrupting Breast Cancer Treatment to Attempt Pregnancy

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the POSITIVE trial, which showed that a temporary interruption of endocrine therapy in women with hormone-responsive ...

breast cancer

Mafalda Oliveira, MD, PhD, on Camizestrant vs Fulvestrant in Advanced Breast Cancer: New Phase II Results

Mafalda Oliveira, MD, PhD, of Spain’s Vall d’Hebron University Hospital and Institute of Oncology, discusses findings from the SERENA-2 trial, which compared the next-generation selective estrogen rec...

Breast Cancer

Survey Finds Sexuality and Fertility Discussions Remain Sidelined Among Young Patients Diagnosed With Breast Cancer

In a new survey, a majority (64%) of patients diagnosed with breast cancer younger than 46 years reported significant impacts to their sexual health, yet 86% of patients reported that their health-car...

breast cancer

Marleen Kok, MD, PhD, on Early Breast Cancer: A Year in Review

Marleen Kok, MD, PhD, of the Netherlands Cancer Institute, discusses the most important advances in early breast cancer treatment during the past year for patients with triple-negative, HER2-positive,...

breast cancer

François-Clément Bidard, MD, PhD: Circulating Tumor Cells May Help Improve Outcomes in Metastatic Disease

François-Clément Bidard, MD, PhD, of the Institut Curie, discusses overall survival results from the STIC CTC trial. To guide the choice between chemotherapy and endocrine therapy for patients with me...

breast cancer

Erica L. Mayer, MD, PhD, on Metastatic Breast Cancer: New Findings on Palbociclib After Prior CDK4/6 Inhibitor and Endocrine Therapy

Erica L. Mayer, MD, PhD, of Dana-Farber Cancer Institute, discusses findings from the PACE study of patients with endocrine- and CDK4/6 inhibitor–pretreated estrogen receptor–positive/HER2-negative me...

breast cancer

Aditya Bardia, MD, MPH, on Elacestrant vs Standard-of-Care Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer

Aditya Bardia, MD, MPH, of Massachusetts General Hospital, discusses results from the phase III EMERALD trial, the first study to demonstrate improved progression-free survival vs standard of care in ...

Judy C. Boughey, MD, on New Findings on the Impact of Breast Conservation Therapy on Local Recurrence

Judy C. Boughey, MD, of Mayo Clinic, talks about why breast-conserving therapy may be a treatment option for some patients with multiple breast lesions. For most patients who present with two or three...

breast cancer

Per Karlsson, MD, PhD: New Data on Breast-Conserving Surgery, With or Without Radiotherapy

Per Karlsson, MD, PhD, of Sweden’s University of Gothenburg and the Sahlgrenska Comprehensive Cancer Center, discusses results from the POLAR study, which was a meta-analysis of three clinical trials ...

Breast Cancer

Elacestrant vs Endocrine Monotherapy in Advanced Breast Cancer: Phase III EMERALD Trial

Elacestrant—an investigational oral selective estrogen receptor degrader (SERD)—achieved longer progression-free survival vs standard-of-care endocrine monotherapy as second- or third-line therapy in ...

Breast Cancer

Impact on Cognitive Function of Adding Chemotherapy to Endocrine Therapy for Breast Cancer

Chemotherapy followed by endocrine therapy led to more cancer-related cognitive impairment compared with endocrine therapy alone in patients with hormone receptor–positive, HER2-negative breast cancer...

Breast Cancer
Genomics/Genetics

Genetic Profiling May Identify Patients With Breast Cancer Who Can Safely Omit Radiation Therapy After Breast-Conserving Surgery

Patients with invasive breast cancer who had low scores on an investigational gene molecular signature had similar rates of local recurrence independent of whether they received adjuvant radiation the...

Breast Cancer

Breast-Conserving Therapy May Be a Treatment Option for Some Patients With Multiple Ipsilateral Breast Lesions

Patients with multiple tumors in a single breast who underwent a lumpectomy followed by radiation therapy had local recurrence rates comparable to those historically observed in patients with a single...

breast cancer

Joannie M. Ivory, MD, MSPH, and Lisa A. Carey, MD, on PAM50 Subtype and 21-Gene Recurrence Scores in Younger and Black Women With Breast Cancer

Lisa A. Carey, MD, and Joannie M. Ivory, MD, MSPH, both of the University of North Carolina at Chapel Hill, discuss the higher frequency and treatment implications of nonluminal A or high-risk tumors ...

breast cancer

Mariana Chavez-MacGregor, MD, MSc, on Adjuvant Endocrine Therapy and Everolimus in HR-Positive, HER2-Negative Breast Cancer

Mariana Chavez-MacGregor, MD, MSc, of The University of Texas MD Anderson Cancer Center, discusses phase III results from the SWOG S1207 trial which was designed to evaluate the role of adjuvant evero...

breast cancer

Nicholas C. Turner, MD, PhD, on New Data on Capivasertib and Fulvestrant for Advanced Breast Cancer

Nicholas C. Turner, MD, PhD, of London’s Institute of Cancer Research and The Royal Marsden, discusses phase III results from the CAPItello-291 clinical trial, which showed that in patients with hormo...

breast cancer

Joseph A. Sparano, MD, on Long-Term Breast Cancer Recurrence and Survival Data from TAILORx

Joseph A. Sparano, MD, of the Tisch Cancer Center at Mount Sinai Health System, discusses long-term clinical outcomes data that continue to show many women with early breast cancer can safely forgo ch...

Breast Cancer

Circulating Tumor Cell Count–Driven Treatment Decisions May Improve Long-Term Outcomes for Patients With Metastatic Breast Cancer

The use of circulating tumor cell counts to guide the choice between chemotherapy and endocrine therapy as first-line treatment for patients with metastatic, estrogen receptor–positive, HER2-negative ...

Breast Cancer

Camizestrant May Be Superior to Fulvestrant in Patients With Hormone Receptor–Positive, HER2-Negative Breast Cancer

The next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival compared to fulvestrant in patients with hormone receptor–positive, HER2-negative breast...

Breast Cancer

Patients With Breast Cancer Who Interrupted Endocrine Therapy to Pursue Pregnancy Did Not Experience Worse Short-Term Recurrence Rates

Patients with breast cancer who paused their endocrine therapy while attempting to conceive experienced short-term rates of breast cancer recurrence similar to patients with breast cancer who did not ...

Breast Cancer

Adding Capivasertib to Fulvestrant May Improve Progression-Free Survival in Patients With Advanced Hormone Receptor–Positive Breast Cancer

In patients with hormone receptor–positive, HER2-negative breast cancer who are resistant to aromatase inhibitors, the addition of the investigational AKT inhibitor capivasertib to fulvestrant doubled...

breast cancer
immunotherapy

Sara A. Hurvitz, MD: New Findings on Neoadjuvant Trastuzumab Deruxtecan and Anastrozole in Early-Stage Breast Cancer

Sara A. Hurvitz, MD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses phase II results from the TRIO-US B-12 TALENT study, which showed that patients with l...

breast cancer
immunotherapy

Sara A. Hurvitz, MD, on Updated Survival Results on T-DXd vs T-DM1 in Metastatic Breast Cancer

Sara A. Hurvitz, MD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses phase III findings from the DESTINY-Breast03 study, which showed that second-line trea...

breast cancer

Ruth O’Regan, MD, on Evaluation of the Breast Cancer Index in Early-Stage Breast Cancer

Ruth O’Regan, MD, of the University of Rochester Medical Center, discusses the Breast Cancer Index (BCI), a genomic assay that can assess the risk of late distant recurrence (5–10 years after diagnosi...

breast cancer

Yara Abdou, MD, on Race and Clinical Outcomes in the RxPONDER Breast Cancer Trial

Yara Abdou, MD, of the University of North Carolina, discusses results from the RxPONDER SWOG S1007 study, which showed that non-Hispanic Black women with hormone receptor–positive/HER2-negative breas...

Breast Cancer
Immunotherapy

T-DXd Yields Superior Outcomes Over Chemotherapy-Based Regimens in Patients Previously Treated With T-DM1: DESTINY-Breast02

Compared with capecitabine-based regimens, fam-trastuzumab deruxtecan-nxki (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic...

T-DXd Yields Longer Overall Survival than T-DM1 as Second-Line Treatment in Patients With HER2-Positive Metastatic Breast Cancer: DESTINY-Breast03

Second-line treatment with fam-trastuzumab deruxtecan-nxki (T-DXd) led to significantly longer overall survival compared with ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive metastati...

Breast Cancer
Immunotherapy

Neoadjuvant T-DXd Shows Clinical Activity in Patients With HER2-Low Breast Cancer

Patients with localized, hormone receptor (HR)-positive, HER2-low breast cancer treated with fam-trastuzumab deruxtecan-nxki (T-DXd) in the neoadjuvant setting had an overall response rate of 75% with...

Breast Cancer

First-Line Ribociclib Plus Endocrine Therapy May Be More Effective Than Combination Chemotherapy in Patients With Aggressive Breast Cancer

In patients with hormone receptor–positive, HER2-negative advanced breast cancer—including patients with visceral crises—those treated with ribociclib plus endocrine therapy had fewer adverse events a...

Breast Cancer

Study Finds Racial Disparity in Prometastatic Tumor Microenvironment Among Patients With Residual Breast Cancer After Neoadjuvant Chemotherapy

Residual tumors from Black patients with estrogen receptor–positive/HER2-negative primary breast cancer treated with neoadjuvant chemotherapy had a higher risk score associated with a biomarker of dis...

Breast Cancer

Genomic Assay May Predict Long-Term Prognosis in Premenopausal Patients With Hormone Receptor–Positive Early-Stage Breast Cancer

Among premenopausal patients with hormone receptor–positive, early-stage breast cancer enrolled in the SOFT trial, those with a high score on the Breast Cancer Index genomic assay had an increased ris...

Advertisement

Advertisement



Advertisement